 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 163
Date: May 26, 2024
A short while ago we reported a slight hiccup in the EGCG: Green Tea extract clinical trial (“Project Alpha”) that we are sponsoring at the Mayo Clinic (MN). You can read the details by clicking on the link below - Latest on Green Tea.
In a nutshell, in January of 2024 the FDA temporarily halted accrual to all human studies of green tea extracts to allow review of newly available toxicity data in beagle dogs that had been fed lots of EGCG. There were reports of liver toxicity in some of the dogs, with the use of some over the counter green tea extracts. During this interruption, FDA required that green tea extract not be given even for patients already on clinical trials. This forced a temporary interruption of Project Alpha trial as well, much to the frustration of patients already in the trial.
After review of the new beagle dog data, the FDA announced in March 2024 the steps necessary to allow reopening of all human trials of green tea extracts, including our own Project Alpha at the Mayo Clinic. The changes required by the FDA were that the Polyphenon E (Trade name of the EGCG extract used in this clinical trial) be given to the patients along with a meal rather than in a fasting state, and dose adjustments made if patients experience evidence of liver irritation on blood tests. The investigators at Mayo Clinic have now incorporated these changes into the design of Project Alpha and the trial has re-opened as of May 2024.
This is exactly how things should be done - full evaluation of all available data, full disclosure of issues as they come up, reasonable and rational changes made to trial designs as they become necessary. If we knew all the answers ahead of time, there is hardly any point in doing clinical trials, is there? We can have dozens of anecdotal stories from patients after using over-the-counter EGCG extracts, or more official sounding reports from “neutraceutical” companies with their own axe to grind, but none of this is worth a hill of beans until and unless we have formal, well-documented clinical trial data from credible researchers. Does green tea EGCG work in controlling CLL, in at least a segment of the CLL patient population? Does it work without toxicity in these patients? What should the dosage be? What are reasonable expectations for patients using it?
Stay tuned: we are on our way to finding credible answers.
And take a bow. Your hard earned dollars made it possible for us to sponsor and fund this important clinical trial.
Be well,
Chaya
______
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
